Target intelligence / Profile preview

RNA, variant U1 small nuclear 14 (RNVU1-14)

Target
RNVU1-14
Molecular classification
Small nuclear RNA (snRNA), Non-coding RNA, Spliceosomal RNA, Other
01

Overview

RNA, variant U1 small nuclear 14 (RNVU1-14) is a member of the variant U1 small nuclear RNAs, a class of short, non-coding RNAs essential for the splicing of pre-mRNA in the major spliceosome[2][1]. Like canonical U1 snRNA, RNVU1-14 recognizes 5' splice sites via base-pairing and plays a critical role in ensuring precise splicing of many genes[1]. RNVU1-14 is part of a family of highly similar variant U1 snRNA genes with complex genomic organization and extensive sequence redundancy, making its analysis and functional dissection technically challenging[1]. Mutations in U1 and its variants, including RNVU1-14, have been implicated in various malignancies due to their effect on global splicing fidelity, leading to widespread aberrant splicing in tumor suppressors and oncogenes[1]. The precise pathogenic contribution of RNVU1-14 relative to other U1 snRNA genes is unclear, but mutations across this gene family are associated with worse outcomes in some cancers[1]. RNVU1-14 is not a protein, enzyme, receptor, or traditional druggable target, but is increasingly recognized for its fundamental regulatory role in RNA biology, with clinical interest as a diagnostic or prognostic biomarker[1][2].

Other names
vU1.14RNU1-37RNVU1-14
02

Biological functions

Pre-mRNA splicingRegulation of splicing fidelityRNA processing
03

Disease associations

Cancer (mutation hotspots in various cancers)Neurodevelopmental disease (by analogy with U1/U4/U5 in spliceosome diseases)Other
04

Safety considerations

No direct concerns for therapy (not a therapeutic target), but mutations may complicate genetic diagnostics due to high sequence complexity and variability[1].
05

Biomarkers

U1 snRNA mutations are suggested as biomarkers for prognosis and patient stratification in specific cancers such as medulloblastoma and chronic lymphocytic leukemia[1].

Beyond the preview

Go deeper on RNA, variant U1 small nuclear 14 (RNVU1-14).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on RNA, variant U1 small nuclear 14 (RNVU1-14).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call